READ-ONLY DIGITIZATION RESULT
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial.
J Clin Oncol · 2026-Jan-20 · PMID 41365333
Panel C提取完成待 EXE 对齐验证
OS
FIG A2. Kaplan-Meier analysis of (A) disease-free survival, (B) distant disease-free survival, and (C) OS in PPS population. Stratified HRs and its 95% CI were reported. Cb, carboplatin; DDFS, distant DFS; DFS, disease-free survival; EC-T, epirubicin plus cyclophosphamide followed by taxanes; EC-TCb, EC-T plus carboplatin; HR, hazard ratio; OS, overall survival; PPS, per-protocol set.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-23T17:06:08+00:00 |